WebDoctor Encyclopedia

Article

TACE and Radioembolisation (SIRT)

What are TACE and radioembolisation?

TACE (transarterial chemoembolisation) and radioembolisation, also called SIRT (selective internal radiation therapy) or TARE (transarterial radioembolisation), are treatments for tumours in the liver. Both deliver treatment directly into the blood vessels that feed the tumour, through a thin tube passed from an artery in the groin or wrist.

In TACE, a chemotherapy drug is injected into the tumour’s artery, followed by tiny particles that block the blood supply. The tumour is starved of oxygen and exposed to a high dose of chemotherapy at the same time.

In radioembolisation, millions of microscopic beads (microspheres) containing the radioactive element yttrium-90 are injected into the artery. They lodge in the small vessels of the tumour and give off radiation from inside it over the following two weeks.

Why the liver suits this approach

The liver has an unusual double blood supply. Healthy liver tissue gets most of its blood from the portal vein, while liver tumours get most of theirs from the hepatic artery. Treatment given into the hepatic artery therefore reaches tumours far more than it reaches the normal liver.

TACE and SIRT compared

Feature TACE Radioembolisation (SIRT)
Active agent Chemotherapy (often doxorubicin or cisplatin) Yttrium-90 microspheres
Blocking the artery A main part of the effect Minimal; the beads are tiny
Planning procedure Usually not needed A preliminary mapping procedure is needed
Number of sessions Often repeated every few months Often a single treatment per liver lobe
Typical stay Usually one night Often a day case
Post-procedure symptoms Post-embolisation syndrome is common Usually milder

Who performs it

These treatments are carried out by interventional radiologists, doctors who specialise in using imaging to guide small instruments through blood vessels. Decisions about whether TACE or SIRT is right for you are usually made by a liver multidisciplinary team, including liver specialists, surgeons, oncologists and radiologists.

1. Key facts at a glance

Feature Details
Type of treatment Liver-directed, catheter-based treatment
Main uses Hepatocellular carcinoma; liver metastases from bowel, neuroendocrine and other cancers
How it is given Through a catheter inserted into an artery in the groin or wrist
Anaesthetic Local anaesthetic with sedation
Procedure time About 1-2 hours
Hospital stay Day case or one night
Repeats TACE is often repeated; SIRT is usually one or two sessions
Main side effects Pain, nausea, fever and tiredness for a few days; rarely liver damage

2. How it works

TACE

Step Effect
1. Catheter in the tumour artery Treatment is aimed at the tumour
2. Chemotherapy delivery The drug is mixed with an oily contrast called lipiodol or loaded onto drug-eluting beads
3. Embolisation Particles block the artery, cutting off blood and oxygen
4. Drug retention The drug stays in the tumour longer because blood flow is slowed
5. Tumour death The combination of oxygen starvation and chemotherapy kills cancer cells

Types of TACE

Type Description
Conventional TACE (cTACE) Chemotherapy mixed with lipiodol, followed by blocking particles
Drug-eluting bead TACE (DEB-TACE) Small beads soaked in chemotherapy release the drug slowly once lodged in the tumour
Bland embolisation (TAE) Particles only, without chemotherapy

Studies comparing these approaches have generally shown similar effectiveness, and the choice usually depends on the experience of the centre.

Radioembolisation

Step Effect
1. Mapping A planning angiogram checks the blood vessels and blocks any that lead to the gut
2. Lung shunt test A tracer scan measures how much would travel to the lungs
3. Microsphere injection Y-90 beads are injected into the artery feeding the tumour
4. Radiation Beta radiation travels only a few millimetres, mainly affecting the tumour
5. Decay Most radiation is delivered within about two weeks

This is a form of internal radiotherapy, related to brachytherapy, in which the radiation source is placed inside the body close to the cancer.

3. Who it is for

Conditions treated

Condition Role
Hepatocellular carcinoma TACE is standard for intermediate-stage disease; SIRT is used for selected early and intermediate tumours and some with vessel invasion
Fibrolamellar carcinoma Sometimes used for liver disease that cannot be removed
Intrahepatic cholangiocarcinoma Used for unresectable disease, often with chemotherapy
Colorectal adenocarcinoma SIRT or chemoembolisation for liver-dominant metastases after other treatments
Gastrointestinal neuroendocrine tumours Liver metastases, to control tumours and hormone symptoms
Pancreatic neuroendocrine tumours Liver metastases
Uveal melanoma Liver metastases, which are common in this cancer

Who may be suitable

Factor Typical requirement
Disease in the liver Tumours mainly or only in the liver
Liver function Reasonably preserved, often Child-Pugh A or early B
General fitness Able to manage day-to-day activities
Blood flow Suitable artery anatomy; for SIRT, limited flow to the lungs
Bile ducts No major blockage of the bile ducts

Who may not be suitable

Situation Reason
Severe liver failure or jaundice High risk of further liver damage
Widespread cancer outside the liver Systemic treatment is usually preferred
Main portal vein blocked by tumour TACE may cause liver damage; SIRT may still be possible
High lung shunt Too much radiation would reach the lungs

4. Before treatment

Step Why it is done
CT or MRI Shows the tumours and blood vessels
Blood tests Liver function, kidney function, clotting and blood counts
Liver function scoring Helps predict safety
SIRT work-up angiogram Maps vessels and measures lung shunt about 1-3 weeks before treatment
Medicines review Blood thinners may need adjusting
Fasting Usually for several hours before the procedure

5. What to expect: step by step

Step What happens
1. Preparation A cannula is placed; you may receive anti-sickness medicine and antibiotics
2. Sedation and local anaesthetic The groin or wrist is numbed; you stay awake but relaxed
3. Catheter insertion A thin tube is passed into the artery
4. Navigation Using X-ray imaging and contrast, the tube is steered into the liver artery
5. Treatment Chemotherapy and particles (TACE) or microspheres (SIRT) are injected
6. Removal The catheter is removed and pressure or a closure device stops bleeding
7. Bed rest Several hours lying flat if the groin was used
8. Observation Pain, nausea and vital signs are monitored
9. Home The same day or next day

After SIRT

A scan is usually done shortly after treatment to show exactly where the microspheres have gone. Radiation precautions are minimal, but close contact with pregnant women and young children may be limited for a short period, as advised.

6. Side effects and risks

Side effect or risk TACE SIRT
Post-embolisation syndrome (pain, fever, nausea) Common, lasting several days Less common, milder
Tiredness Common Common, may last weeks
Groin bruising Common Common
Liver function worsening Possible, especially with cirrhosis Possible; radiation-induced liver disease is rare
Liver abscess Rare Rare
Gallbladder inflammation Rare Rare
Stomach or duodenal ulcer Rare Rare, if beads reach the gut
Radiation pneumonitis Not applicable Very rare, if too much reaches the lungs
Hair loss Uncommon Not expected

7. Results and outlook

Study Main finding
Llovet and colleagues, unresectable HCC (112 people) Chemoembolisation improved two-year survival to 63% compared with 27% with supportive care alone (Llovet et al., 2002)
Lo and colleagues, unresectable HCC in Asian patients (80 people) Lipiodol chemoembolisation with cisplatin raised two-year survival to 31% versus 11% with symptomatic care (Lo et al., 2002)
SARAH, locally advanced HCC (459 people) SIRT did not lengthen survival compared with sorafenib (8.0 versus 9.9 months), but some side effects such as diarrhoea and fatigue were less frequent (Vilgrain et al., 2017)

The two 2002 trials established TACE as a standard treatment for intermediate-stage liver cancer. SIRT has not beaten tablet treatment in advanced disease, but it is often used for earlier tumours, for people who cannot have TACE, and as a way to shrink tumours before surgery or transplant.

Bridging and downstaging

People waiting for a liver transplant may have TACE or SIRT to stop the cancer growing while they wait. This is called bridging. In others whose tumours are slightly too large or too many for transplant, these treatments may shrink the cancer to within the accepted limits, which is called downstaging. Success depends on careful selection and close follow-up scans.

Combining with medicines

Researchers are testing TACE and SIRT together with immunotherapy and targeted drugs. The idea is that the local treatment kills tumour cells and releases signals that help the immune system, while the medicines control cancer elsewhere. Several trials have reported encouraging results, and these combinations may become more common.

What results mean for you

For most people with intermediate liver cancer, TACE and SIRT control the cancer rather than cure it. They can keep tumours in check for many months, and sometimes for years. In selected people, they can shrink tumours enough to allow surgery, ablation or a liver transplant.

8. Recovery and aftercare

Recovery timeline

Period What to expect
First 1-3 days Pain, fever and nausea, especially after TACE
Week 1 Tiredness and poor appetite gradually improve
Weeks 1-2 Return to normal light activities
4-12 weeks Scan to check response
Every few months Repeat TACE or other treatment as needed

Practical tips

  • Rest for the first few days and gradually increase activity
  • Take pain relief and anti-sickness medicine as prescribed
  • Check the puncture site for swelling or bleeding
  • Seek help for high fever, worsening pain, yellow skin or confusion
  • Avoid alcohol, which can strain the liver

Living with liver cancer

Liver cancer often develops alongside long-term liver disease. Looking after the liver through treating hepatitis, avoiding alcohol, managing weight and controlling diabetes helps both the cancer treatment and overall health. Specialist liver nurses and patient groups can offer support.

Eating well

Poor appetite and early fullness are common with liver cancer. Small, frequent meals with enough protein help maintain strength. A dietitian can advise on salt intake if fluid builds up in the abdomen.

9. Alternatives

Alternative When it is considered
Surgical resection Tumours that can be removed with enough healthy liver left
Liver transplant Selected people with HCC and cirrhosis
Thermal ablation Small tumours
Stereotactic or proton radiotherapy Selected tumours; see proton beam therapy
Immunotherapy Advanced HCC; see immune checkpoint inhibitors
Targeted tablets Sorafenib, lenvatinib and others
PRRT Neuroendocrine liver metastases
Supportive care When liver function is poor

Ask your team which option is most likely to help you, and what the next step would be if the first treatment does not work.

10. Frequently asked questions

Question Answer
Is it an operation? No; it is done through a small puncture in an artery
Will I be asleep? Usually sedated but awake
Will I lose my hair? Hair loss is uncommon because little chemotherapy reaches the rest of the body
How many treatments will I need? TACE is often repeated; SIRT is usually one or two sessions
Will I be radioactive after SIRT? Only slightly, mainly inside the liver; your team will give simple advice
Can it help me get a transplant? Sometimes, by shrinking tumours to within transplant criteria
Which is better, TACE or SIRT? It depends on the tumour, liver function and local expertise

11. Questions to ask your care team

  • Would TACE or SIRT suit me better, and why?
  • How is my liver function, and is treatment safe?
  • How many sessions might I need?
  • What side effects should I expect?
  • Could this help me qualify for surgery or transplant?
  • When will I have a scan to check the result?
  • What are the alternatives if it does not work?

Resources

  1. Llovet, J.M. et al. (2002) ‘Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial’, The Lancet, 359(9319), pp. 1734-1739.
  2. Lo, C.M. et al. (2002) ‘Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma’, Hepatology, 35(5), pp. 1164-1171.
  3. Vilgrain, V. et al. (2017) ‘Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial’, The Lancet Oncology, 18(12), pp. 1624-1636.
  4. National Cancer Institute (2026) Primary Liver Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/liver/hp/adult-liver-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.